# Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

> **NCT07332091** · PHASE2 · RECRUITING · sponsor: **CSL Behring** · enrollment: 84 (estimated)

## Conditions studied

- Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis

## Interventions

- **DRUG:** Vamifeport
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07332091
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-22
- **Primary completion:** 2028-03-06
- **Final completion:** 2028-04-06
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07332091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07332091, "Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07332091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*